|
 Bioaltus Pharmaceuticals has emerged as a dynamic leader in the pharmaceutical industry, driven by its commitment to innovation, global expansion, and a focus on unmet medical needs. From its humble beginnings as a research-centric organization to its evolution into a global commercial pharmaceutical entity, Bioaltus has made significant strides in drug discovery, regulatory compliance, and sustainable practices.
Dr. Ankit Varshney, Founder & Director of Bioaltus Pharmaceuticals, in an exclusive interview with Shardul Nautiyal, explores the company’s growth, the challenges facing MSMEs, the impact of AI and IoT in clinical trials, and the future of the Indian pharmaceutical industry on the global stage. Bioaltus’ ambitious expansion plans and upcoming product launches further demonstrate its dedication to advancing healthcare worldwide. Excerpts
Can you tell us about the journey of Bioaltus Pharmaceuticals and how the company has evolved over the years?
Bioaltus Pharmaceuticals began as a small, research-focused organization with a mission to address unmet medical needs using advanced scientific solutions. Our first major breakthrough was the development of Imikro Nano technology, which revolutionized the treatment of diabetes with more efficient and smaller tablets.
This success laid the foundation for our expansion into various therapeutic areas, including cardiology, nephrology, neurology, and pain management. Over time, we have transformed into a global pharmaceutical company with a diverse portfolio, regulatory approvals for major drugs, and a growing international presence.
Our journey has been marked by continuous innovation, with significant investments in research and development of new therapeutic molecules and drug delivery systems. Today, Bioaltus is recognized for its commitment to cutting-edge science, regulatory excellence, and a robust pipeline of promising new drugs aimed at addressing the evolving needs of patients worldwide.
As a leading MSME in the pharmaceutical industry, what challenges do you face in regulatory compliance?
Navigating the complex regulatory landscape is one of the most significant challenges for MSMEs like Bioaltus. The requirements can be overwhelming, especially for smaller companies with limited resources. Compliance costs, constantly changing regulations, and difficulties in accessing timely and accurate information can hinder growth. Many MSMEs also lack the legal expertise to fully comprehend and implement necessary compliance measures. These challenges underscore the need for more streamlined processes, greater governmental support, and access to clear, concise guidance.
What actions should the government take to help Indian pharmaceutical companies grow and enhance their global competitiveness?
The government has a critical role to play in fostering the growth of Indian pharmaceutical companies and strengthening their global presence.
First and foremost, incentivizing research and development through tax breaks, grants, and easier access to funding is essential. Streamlining the regulatory process for drug approvals and exports can significantly reduce the time-to-market for new drugs, giving Indian companies a competitive advantage on the international stage.
Moreover, investing in workforce development through specialized training programs will ensure that the industry has the skilled talent necessary for global success. Lastly, fostering international collaborations and establishing pharmaceutical-specific trade agreements will open new markets and facilitate smoother entry into existing ones. These government initiatives would significantly bolster the growth and consolidation of Indian pharmaceutical companies in the global marketplace.
With rising compliance costs and narrowing profits, what kind of support do you hope to see from the government for pharmaceutical R&D?
Given the financial pressures facing the pharmaceutical industry, particularly from rising compliance costs and narrowing profit margins, government support for R&D is more critical than ever. We hope to see targeted incentives such as tax breaks and grants specifically for pharmaceutical R&D. Establishing dedicated funds or providing low-interest loans for high-risk research could also give companies the capital needed to pursue breakthrough innovations.
Additionally, streamlining regulatory approval processes would reduce bureaucratic obstacles, enabling companies to bring new, life-saving drugs to market more quickly. Encouraging collaborations between industry, academia, and government research institutions could further drive innovation and help ensure that India remains at the forefront of pharmaceutical advancements.
Could you provide insights into the recent R&D initiatives and product launches by Bioaltus Pharmaceuticals?
At Bioaltus, our R&D initiatives are focused on addressing critical healthcare needs and advancing the boundaries of medical science. We have deeply invested in developing novel therapeutic molecules across multiple therapeutic areas, including diabetes, cardiology, and pain management. We are also working on innovative drug delivery systems, such as advanced oral solid dosage forms, including bilayer tablets, to enhance patient compliance and therapeutic efficacy.
Recently, we successfully commercialized several new products, including Ticagrelor, Pulmocoxib, Linagliptin, Sitagliptin, and Ferric Pyrophosphate (Liposomal). These products reflect our ongoing commitment to improving patient outcomes through innovative treatments.
How can AI and IoT tools help reduce the expenses of conventional clinical trials and expedite drug discovery?
AI and IoT technologies are revolutionizing the pharmaceutical industry by making clinical trials more efficient and cost-effective. AI can analyze vast amounts of data to identify promising drug candidates, predict clinical outcomes, and optimize trial designs, significantly reducing the time and cost associated with drug development. IoT devices, such as wearable health monitors, allow for real-time patient data collection, reducing the need for frequent clinic visits and enhancing trial monitoring.
Together, AI and IoT are accelerating the drug discovery process, making it more efficient, faster, and less costly, ultimately benefiting patients by bringing new treatments to market more quickly.
Could you explain the importance of data integrity in the pharmaceutical value chain?
Data integrity is the backbone of the pharmaceutical value chain, ensuring that all information from drug development to manufacturing and testing is accurate, complete, and reliable. Maintaining high standards of data integrity is essential for meeting regulatory requirements, ensuring product quality, and safeguarding patient safety. Any breach in data integrity can have severe consequences, including the production of unsafe drugs, regulatory penalties, and loss of public trust. Therefore, ensuring that all data is accurate and protected against tampering is critical to the success of pharmaceutical companies.
How is nanotechnology revolutionizing sustained-release drug delivery systems in pharmaceuticals?
Nanotechnology is playing a transformative role in sustained-release drug delivery systems by enabling the design of tiny, precise nanoparticles that can release medication gradually over time. This allows for more controlled drug delivery, reducing the frequency of doses required, minimizing side effects, and improving overall treatment effectiveness. By targeting specific areas of the body, nanotechnology ensures that drugs are delivered exactly where they are needed, enhancing patient outcomes and convenience.
How is the pharmaceutical industry adapting to sustainability?
Sustainability has become a key focus for the pharmaceutical industry, with companies like Bioaltus adopting green manufacturing processes, reducing waste, and implementing sustainable sourcing practices. We are investing in energy-efficient technologies, minimizing environmental impact through responsible waste management, and exploring biodegradable packaging solutions. Our commitment to sustainability extends to reducing our carbon footprint by investing in renewable energy and exploring carbon offset programs, reflecting our dedication to preserving the environment while advancing healthcare.
Could you share Bioaltus’ expansion plans and upcoming product launches?
Bioaltus is embarking on an exciting expansion with the construction of a new state-of-the-art manufacturing plant in Sarigam, Gujarat. This facility, dedicated to producing high-quality oral solid dosage forms, will meet stringent EU GMP standards and become one of the largest bilayer tablet manufacturing plants in the region. This expansion will significantly boost our production capacity and support our growing partnerships with leading pharmaceutical companies in India and beyond.
In addition to our manufacturing expansion, we are preparing to launch two groundbreaking new molecules: empagliflozin combinations for diabetes management and pulmocoxib combinations for treating osteoarthritis. These launches reflect our commitment to advancing healthcare through innovation and expanding our therapeutic offerings to meet the evolving needs of patients.
What are your final thoughts on the growth prospects of the Indian pharmaceutical industry?
I am highly optimistic about the future of the Indian pharmaceutical industry. With a skilled workforce, cutting-edge technological advancements, and a tradition of innovation, India is well-positioned to maintain and expand its global leadership in pharmaceuticals. However, it is essential that both the industry and the government work together to address challenges such as regulatory complexities, rising costs, and the need for greater R&D investment. By overcoming these hurdles, the Indian pharmaceutical industry can continue to deliver affordable, high-quality medicines to patients around the world and expand its global footprint.
|